· Significant reduction of incidence of severe mucositis · Improved oral mucositis related symptoms and decreased adverse events related to radiotherapy · Good Safety profile · Strong Compliance to treatment Trial Advisory Board validated data as supportive to enter into Phase III trial PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced positive preliminary top -line results from its Phase II clinical trial of Validive® (mucoadhesive buccal tablet MBT clonidine Lauriad®) for prevention of severe oral mucositis (OM). Oral mucositis is a radio/chemotherapy related condition occurring very frequently in patients undergoing head and neck cancer treatment. Based on the well-established WHO scale, OM is considered as “non severe” for grades 0 to 2, based on level of pain and burden for the patients. From grade 3 to 4, OM is rated severe, based on symptoms such as pain and mouth dryness which prevents patients from drinking and eating and induces increased hospitalization and treatment breaks. With no curative or preventive treatment currently, OM represents a serious unmet medical need for the patients. Onxeo has performed a large international randomized, double-blind, placebo -controlled Phase II trial comparing the efficacy and safety of Validive® 50 μg and 100 μg applied once daily to those of placebo in the prevention and treatment of chemoradiation therapy-induced severe oral mucositis in 183 patients with head and neck cancer. All patients received a postoperative radiochemotherapy with a mean cumulative dose of 61 Gray in combination with cisplatin-based chemotherapy in most of the cases. Endpoints were to compare the incidence, severity, time to onset and duration of severe OM as well as use of opioids and other adverse events related to cancer radiation treatment between the Validive® pooled groups and placebo. They were evaluated twice a week during the whole radiotherapy treatment. The key results of the Phase II study showed: . Significant decrease in the incidence of severe oral mucositis (grades 3 and 4) in the Validive® pooled arms versus placebo. Overall incidence of severe OM was 45% in the Validive® groups, with a maximum absolute decrease of 16% compared to placebo. . Occurrence of severe OM has been delayed in the Validive® groups compared to placebo. . Higher doses of radiation have been received by the Validive® treated patients before severe OM occurred. . Improvement of critical conditions related to severe oral mucositis and radiation therapy, especially dysphagia, nausea and vomiting in both Validive® groups. . No significant difference in efficacy observed between Validive® 50 μg and 100 μg groups. . In terms of safety, Validive® showed a good safety profile with no major difference in the nature, incidence and severity of adverse events in the placebo and the Validive® groups. At last, patient’s compliance was very high, with more than 80% of patients applying Validive® or placebo tablets on the gum every day during radiation therapy as requested in the trial. The trial Advisory Board gathering Pr Michael Henke (Freiburg Germany), Pr René -Jean Bensadoun (Poitiers, France) and Pr Jordi Giralt (Barcelona, Spain), trial’s coordinators, and Pr Steve Sonis, all international experts in oral mucositis, met to analyze and validate the main preliminary results. Based on these preliminary data the Board has recommended pursuing the development of Validive® with the initiation of a Phase III trial in the same patient population. The company plans to initiate this trial in 2015. Validive® was granted a fast track designation by the FDA in January 2014, allowing facilitated interactions with the FDA and optimized development time and review period for drugs investigated as treatments for serious or life -threatening diseases with a high unmet medical need. Moreover, Validive® enjoys the orphan status in Europe, enabling optimization of the product’s development plan in terms of cost and duration, as well as strengthening its protection (market exclusivity). “All investigators in the study were looking forward these positive preliminary results which confirm the interest of Validive® as a highly promising treatment to tackle a devastating inflammation in heavily stressed patients, with virtually no side effects,” comments Judith Greciet, CEO of Onxeo. “With these promising positive Phase II results for Validive® and the product ready to enter Phase III, Onxeo now has a second program reaching the last stage of development, ahead of registration. This is a crucial step that significantly reinforces Validive®’s value and makes of this strong asset a success for Onxeo. I take the opportunity of this great achievement to thank eveybody, investigators, clinical and non-clinical experts as well as our internal teams for their help and strong support in the development of Validive.” About Severe Oral Mucositis Severe oral mucositis is a particularly invalidating pathology occurring in more than 60% of patients treated with radio/chemotherapy for head and neck cancer and has currently no validated curative or preventive treatment. It may induce intense oral pain and eating disability requiring enteral or parenteral nutritional support. Thirty percent of patients need to be hospitalized as a result and symptoms can force patients to stop treatment for an undefined period thus reducing treatment efficacy. Validive® is a therapeutic application of clonidine based on the mucoadhesive technology Lauriad®. Clonidine stimulates the alpha-2 adrenergic receptors traditionally used to treat high blood pressure. It stimulates these receptors in the brain. This leads to a decrease in peripheral resistance and thus a lowering of blood pressure, as well as a reduction in heart rate and renal vascular resistance. However, clonidine also acts as an agonist of the alpha-2 adrenergic receptors on leucocytes and macrophages, thereby decreasing the expression of the pro -inflammatory genes and the release of cytokines IL6, IL1β and TNFα. This effect leads to a reduction in the pro-inflammatory mechanisms. It also acts on the anti-inflammatory mechanisms by increasing the release of TGF β. Clonidine therefore has the following properties: · Painkilling properties due to changes in the inflammatory response and its direct action on nociceptors; · Anti-inflammatory properties due to its action on the expression of the pro -inflammatory genes and the resulting release of cytokines IL6, IL1 β and TNFα and due to the release of TGF β. About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis Beleodaq® (belinostat): Registered and available in the USA for peripheral T -cell lymphoma For more information, visit the website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3 A %2F%2Fwww.onxeo.com&esheet=50973460&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=1eaa2a04bb2b9c72e6b24bf857775d9a) Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf -france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww . amf-france.org&esheet=50973460&newsitemid=0&lan=en -US&anchor=http%3A%2F%2Fwww.amf -france.org&index=2&md5=0c329569c2c7ab5b202073f94aeb6ceb)) or on the company’s website (www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F w ww.onxeo.com&esheet=50973460&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=3&md5=29320791e70793322f9099f2cde6d8d6)). Onxeo S.A. Judith Greciet, CEO, +33 1 45 58 76 00 j.greciet@onxeo.com or Nicolas Fellmann, CFO, +33 1 45 58 76 00 n.fellmann@onxeo.com or Alize RP Caroline Carmagnol / Sophie Colin, +33 6 64 18 99 59 / +33 6 31 13 76 20 caroline@alizerp.com / scolin@alizerp.com
Onxeo S.A.: Positive Phase II preliminary results of
Top 10 Most Recent News Articles
Modexus Opens a $500 Million Buyback With Real Caveats
A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...
Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence
Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...
Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check
Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...
Continue Reading
Markel Elevates War Risk Expertise in London Market
A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...
Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand
Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...
Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It
Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...
Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data
A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...
Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test
Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...
Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run
Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...
Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars
A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...
Continue Reading